Barrett's esophagus predisposes to adenocarcinoma of the esophagus and survival in oesophageal adenocarcinoma is low.
Dr Apollo Kenneth Musana and colleagues from Wisconsin, USA studied patients diagnosed with Barrett's esophagus in the Marshfield Epidemiologic Study Area.
|Long-segment Barrett's esophagus was present in 52% of patients|
|American Journal of Gastroenterology|
The team estimated the prevalence of diagnosed Barrett's esophagus, as well as the annual incidence of initial diagnosis of Barrett's esophagus.
The researchers then characterized the demographics of patients diagnosed with Barrett's esophagus.
The team reviewed medical records of patients diagnosed with Barrett's esophagus up to 2002.
The esophagogastroduodenoscopy reports were reviewed to establish the presence of columnar epithelium.
All slides were retrieved and reviewed by a gastrointestinal pathologist to establish the presence of intestinal metaplasia and dysplasia.
Chart abstraction was conducted using a standardized form.
The researchers confirmed Barrett's esophagus in 216 patients.
The team found all were white, 76% were male, and 81% had a hiatal hernia.
Median age at diagnosis was 66 years.
The team found long-segment Barrett's esophagus was present in 52% of patients.
The prevalence of histologically confirmed Barrett's esophagus in Marshfield Epidemiologic Study Area was 262 per 100,000 people.
The team found the incidence of an initial diagnosis of Barrett's esophagus between 1996 and 2002 was 33 per 100,000 person-years.
This did not change significantly over the study period despite an increase in esophagogastroduodenoscopy rates.
At the initial diagnosis, 42% of the patients were on proton pump inhibitors.
The researchers identified dysplasia in 25% of patients.
Dr Musana's team concluded, "The incidence of initial diagnosis of Barrett's esophagus in a stable white population did not change significantly over a 7-year period, despite an increase in esophagogastroduodenoscopy rates."